Home | Investor Relations
Stock Quote (NASDAQ: NSTG)
- 0.02
Day High:
Day Low:
4:00 PM ET on Mar 28, 2017
Delayed at least 20 minutes.
Provided by eSignal.

Search Investor Relations

Investor Relations

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

View all »Events & Webcasts

WEBCASTMar 07, 2017 at 8:40 AM ET
Cowen and Company 37th Annual Health Care Conference
WEBCASTMar 01, 2017 at 4:30 PM ET
Nanostring 2016 Fourth Quarter Financial Results
WEBCASTJan 10, 2017 at 10:30 AM PT
J.P. Morgan 35th Annual Healthcare Conference